Treatment Of Colorectal Tumors Research Articles

Diagnosis and treatment of colorectal tumor

Diagnosis and treatment of colorectal tumor

Endoscopic diagnosis and treatment of colorectal tumors and future prospects

Endoscopic diagnosis and treatment of colorectal tumors and future prospects

Analysis of effect of colonoscopy combined with laparoscopy in the treatment of colorectal tumors.

Colorectal cancer is one of the most common digestive tract tumors. To evaluate the feasibility and safety of laparoscopic colorectal cancer surgery. This study retrospectively analyzed early postoperative clinical data of 48 patients with colorectal cancer treated in our hospital between 2015 and 2021, of which 21 underwent laparoscopic colorectal surgery, and 27 underwent laparotomy. There was no significant difference in clinical data. Patients were included if they had colorectal cancer (confirmed by colonoscopy and biopsy pathological examination before surgery), were evaluated for possible radical surgery before surgery, and had no intestinal obstruction, tumor invasion of adjacent organs (by digital rectal examination and preoperative abdominal color Doppler ultrasound, CT confirmed) and no other history of abdominal surgery. Using the method of clinical control study, operation time, intraoperative blood loss, postoperative general condition, surgical lymph node removal (postoperative pathology), surgical complications, gastrointestinal function recovery, surgical before and after blood glucose, body temperature, white blood cells, pain visual analog scale (VAS) and other conditions were compared and analyzed to determine feasibility and safety of laparoscopic surgery for colorectal cancer. Colorectal cancer was successfully removed by laparoscopic radical resection without any significant problems or surgical fatalities. Age, gender, tumor location, stage, and duration of surgery did not differ between laparoscopic and laparotomy operations. Compared to laparotomy, postoperative eating, bowel movements, and blood sugar levels improved. Variations in the length of surgically removed specimens after VAS measurements revealed open and laparoscopic operations. The overall lymph node count was 10.8 ± 1.6, with no variation between the two techniques. Laparoscopic colorectal cancer radical surgery is safe and feasible. Also, it has the advantages of minimally invasive surgery. Laparoscopic colorectal cancer radical surgery can comply with the principles of oncology revolutionary.

Meta-analysis of clinical efficacy and safety of transanal endoscopic microsurgery and endoscopic submucosal dissection in the treatment of rectal tumors.

The aim of the article was to systematically evaluate the clinical efficacy and safety of transanal endoscopic microsurgery (TEM) and endoscopic submucosal dissection (ESD) in the treatment of rectal tumors. Control studies were conducted on cases included in the electronic databases Medline, Embase, Cochrane Library, and CNKI. Patients with colorectal tumors were included in the TEM and ESD groups for treatment, with the main indicators being R0 resection rate, postoperative perforation and bleeding incidence, and tumor recurrence rate. The meta-analysis was carried out using RevMan 5.3 software. A total of 10 studies were included, with 736 patients. The analysis showed that for the recurrence rate in the TEM group compared to ESD, OR = 1.23, 95% CI = 0.56-2.72, p = 0.60; for the R0 resection rate between the TEM group and ESD group, OR = 1.35, 95% CI = 0.82-2.22, p = 0.24; for the incidence of perforation in the TEM and ESD groups, OR = 0.59, 95% CI = 0.25-1.40, p = 0.23. The inter-group comparison of these three items was statistically significant. Compared with the ESD group, the hospitalization time and the incidence of bleeding of the TEM group were both lower, with SD = 0.48, 95% CI = 0.26-0.69, p < 0.001 and OR = 0.35, 95% CI = 0.13-0.92, p = 0.03. The differences were statistically significant. Both TEM and ESD endoscopic treatment techniques can achieve a higher R0 resection rate and lower risk of tumor recurrence in the treatment of colorectal tumors. However, TEM may have higher surgical safety than ESD technology, and can shorten postoperative hospitalization time and lower postoperative bleeding rate.

Progress of laparoscopy and endoscopy cooperative surgery for early colorectal tumors

Cooperative laparoscopic or robotic-endoscopic surgery has emerged as a promising approach for the treatment of early-stage colorectal cancers that are difficult to treat with endoscopic techniques alone. Cooperative surgery allows organ and function preservation by complementing the advantages of each modality, providing minimally invasive, precise and personalized treatment options. Laparoscopic-endoscopic cooperative surgery includes laparoscopic-assisted endoscopic resection, combined laparoscopic-endoscopic full-thickness resection, endoscopic-assisted laparoscopic wedge resection, endoscopic-assisted laparoscopic segmental resection, and laparoscopic-endoscopic cooperative surgery with sentinel lymph node dissection. Nearly three decades of clinical research and practice have demonstrated the safety and efficacy of laparoscopic and endoscopic cooperative surgery in the treatment of colorectal tumors. With the progress of the minimally invasive concept, the development of minimally invasive technology and the innovation of minimally invasive equipment, laparoscopy and endoscopy cooperative surgery is expected to have a proper place in the treatment of colorectal tumors.

Does postcholecystectomy increase the risk of colorectal cancer?

With the increasing number of cholecystectomy and the high proportion of colorectal cancer in malignant tumors, the question of whether cholecystectomy is a risk factor for colorectal disease has been widely concerned. After reviewing the literature at home and abroad, the authors will summarize the research progress of the correlation between the occurrence of colorectal tumors after cholecystectomy, in order to provide help for the prevention and treatment of colorectal tumors.

Abstract 182: Bridging gaps in translational biology: Exploring pharmacokinetic/pharmacodynamic/efficacy relationships and combination treatments in 3D tumor models using a microphysiological system

Abstract Accurate profiling of pharmacokinetic (PK) and pharmacodynamic (PD) parameters is critical in the discovery and development of new oncology drugs, schedules and combinations. Predicting these parameters pre-clinically is essential to determine efficacious doses required in clinical treatment. The PK/PD/efficacy relationship has traditionally been characterized in xenograft models, owing to an absence of viable in vitro alternatives. However, murine/human PK parameters can vary for many compounds. To explore PK/PD/efficiency relationships on 3D tumor models and organoids, we have developed a microphysiological system (MPS) able to mimic or reverse translate clinical/in vivo drug exposure (PK) profiles on an in vitro system. The MPS can deliver up to two different drugs to tumor models in monotherapy or combinations, using customizable PK profiles and treatment schedules, by stepwise addition and removal of cell culture medium in a regular 24-well plate format. We first recapitulated the in vivo PK/PD relationship for a PI3K inhibitor (BYL719- t1/2 6 hours, equivalent to 50 mg/kg murine oral dose), used to treat an A549 non-small cell lung carcinoma model. Following BYL719 exposure in the MPS device cellular p-AKT levels (biomarker of PI3K pathway activity) fell by up to 90%, but then recovered to pre-dosed levels over a 24-hour period as drug concentrations in the tumor reduce, as observed in vivo. This effect lacks in standard in vitro bolus experiments. Next, we explored whether the MPS could recapitulate in vivo effects of combining topoisomerase inhibitors with DNA-damage-response inhibitors (DDRi) in the treatment of colorectal tumors. Being almost non-toxic to normal cells, DDRi’s enhance DNA damage induced by topoisomerase inhibitors. 3D colorectal tumor models were treated by the MPS device for six days with monotherapy or combination therapy of the two compounds (SN38 Cmax = 20 nM, DDRi Cmax = 162 nM), recapitulating their in vivo PK profiles. Viability assays showed the benefits of combination therapy (viability 48.5% vs controls) over topoisomerase inhibitor monotherapy (viability 58.3% compared vs controls), with efficacy rates consistent with in vivo observations, rather than static 2D in vitro cultures which were over predictive. Overall, our MPS is able to accurately capture PK/PD/efficacy relationships using in vitro cultures. This approach will enable a greater understanding of drug properties and optimal treatment regimens to ultimately enable better design of clinical studies. Citation Format: Tudor Petreus, Tomasz Kostrzewski, Dharaminder Singh, David Hughes. Bridging gaps in translational biology: Exploring pharmacokinetic/pharmacodynamic/efficacy relationships and combination treatments in 3D tumor models using a microphysiological system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 182.

Self-completion method of endoscopic submucosal dissection using the Endosaber for treating colorectal neoplasms (with video)

Endoscopic submucosal dissection (ESD) is effective for the treatment of colorectal neoplasms. We have developed a self-completion ESD (S-ESD) using Endosaber without requiring additional instruments or assistance. This prospective cohort study was conducted to investigate the feasibility of S-ESD for colorectal neoplasms. Patients with colorectal neoplasms measuring 20–40 mm in size were enrolled. A single operator, without assistance, performed ESD using only the Endosaber. The primary outcome was the success rate of S-ESD. Secondary outcomes included procedure time, the rates of en bloc, complete, and curative resection, and complication rates, including the incidence of perforation and delayed bleeding. In total, 15 patients with 15 lesions were enrolled. The median size of the resected lesions was 28 mm (interquartile range 25–29 mm). S-ESD success rate of 100% was achieved. The median procedure time was 44 min (29.5–53.5 min). We observed en bloc, complete, and curative resection rates of 100%, 93.3%, and 86.7%, respectively, and a complication rate of 6.7% (perforation: 0%, delayed bleeding: 6.7%). S-ESD for colorectal neoplasms was successfully performed with favorable treatment outcomes and low complication rates. S-ESD reduces the number of devices and extent of assistance, making S-ESD a simple and cost-effective procedure.

Diagnosis and treatment of colorectal tumors: Differences between Japan and the West and future prospects.

Dye‐based chromoendoscopy has long been used routinely for endoscopic diagnosis of gastrointestinal tumors including colorectal tumors in Japan. In the West, on the other hand, dye‐based chromoendoscopy was not so commonly used. However, with the development of narrow band imaging (NBI), image‐enhanced endoscopy diagnosis has rapidly increased in the West.The most critical difference between Japan and the West is the histopathological evaluation of the lesions, which determines a major cause of differences in diagnostic and treatment strategies. In the West, intramucosal adenocarcinoma is not diagnosed until the cancer has invaded submucosal layer. In Japan, on the other hand, cancer is mainly diagnosed based on nuclear and structural atypia, and thus intramucosal adenocarcinoma is diagnosed in lesions that correspond to high‐grade adenoma in the West.In the West, since intramucosal carcinoma is not diagnosed by pathology, all benign adenomas are treated by piecemeal endoscopic resection, and only cancer invading the superficial submucosal layer is indicated for endoscopic submucosal dissection (ESD). Because of the risk of lymph node metastasis in the deep submucosal invasion, the European Society of Gastrointestinal Endoscopy and American Society for Gastrointestinal Endoscopy guidelines state that only superficial submucosal cancer is an indication for ESD. Unfortunately, it is impossible to selectively extract only superficial submucosal invasive cancer even with the use of magnified NBI and pit pattern observation. Therefore, we think that pathologists need to diagnose intramucosal adenocarcinoma with the potential to invade the submucosal layer based on the nuclear and structural atypia. Consequently, intramucosal adenocarcinoma and superficial submucosal cancers should be considered for en‐bloc ESD.

EPoster

Background and Aim: Aberrant crypt foci (ACF) in the rectum have been reported to correlate with the risk of colorectal tumorigenesis and are useful biomarkers for predicting the risk of colorectal cancer because they are quantitative and can be evaluated in a short period of time. Leukotriene receptor antagonists (LTRAs) have been reported to have inhibitory effects on various carcinomas, but their effects on colorectal cancer are unknown. Based on the report that colorectal cancer overexpresses the cysteinyl leukotriene receptor, we investigated whether LTRA medication affects the number of ACF. Methods: The eligibility criteria were patients who were between 30 and 80 years old, had colorectal tumors that were suitable for endoscopic resection, and had at least five ACFs in the rectum. First, 30 patients were enrolled in the LTRA group, who were treated with montelukast sodium 10 mg for 8 weeks, and rectal ACFs were counted during treatment of colorectal tumors. 10 patients in the no medication follow-up group were enrolled as the control group. Results: One patient in the control group was not examined due to the COVID-19 pandemic, so we examined 30 patients in the LTRA group and 9 patients in the control group. The number of rectal ACFs decreased to -2.4 (SD 2.2) in the LTRA group compared to baseline, while there was no decrease to 0.4 (SD 2.3) in the control group, and there was a significant difference in ACF trends between the two groups (P = 0.002). The Ki67 labeling index, which is a cell proliferation activity, was -1.34 (SD 2.68) in the LTRA group compared to baseline, while it was 0.13 (SD 1.89) in the control group, but there was no significant difference between the two groups. Conclusion: The LTRA treatment decreased rectal ACF and may reduce the risk of colorectal cancer.

Utility of under-gel endoscopic mucosal resection with partial submucosal injection for a laterally spreading tumor.

Conventional endoscopic mucosal resection (EMR) is a widely used technique in the treatment of colorectal tumors. When resecting laterally spreading tumors (LSTs) with conventional EMR, the distal edge is difficult to dissect and tends to be piecemealed. However, the nongranular pseudodepressed type (LST-NG-PD) has a high risk of malignancy, requiring en bloc resection [1]. Endoscopic submucosal dissection (ESD) can ensure high en bloc resection rates, but it also has drawbacks such as high perforation rates, high cost, and long procedure times. Binmoeller et al. introduced underwater EMR (UEMR) as a useful alternative to ESD for LSTs [2]; however, treating the distal end remains a challenge and could cause segmental resection. In addition, the use of water in UEMR may impair clarity of view if bleeding occurs. Partial submucosal injection improves visualization of the distal edge [3], and gel immersion improves the endoscopic visual field [4] [5]. Here, we report that under-gel EMR with partial submucosal injection is an effective means of achieving en bloc resection of LST-NG-PD ([Video 1]).

IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor.

Interaction between a tumor and its microenvironment is important for tumor initiation and progression. Cancer stem cells (CSCs) within the tumor interact with a microenvironmental niche that controls their maintenance and differentiation. We investigated the CSC-promoting effect of factors released from myofibroblasts into the microenvironment of early colorectal cancer tumors and its molecular mechanism. By messenger RNA microarray analysis, expression of HES1, a Notch signaling target, significantly increased in Caco-2 cells cocultured with 18Co cells (pericryptal myofibroblasts), compared to its expression in Caco-2 cells cultured alone. Caco-2 cells cultured in 18Co-conditioned media (CM) showed a significant increase in CD133+CD44+ cells and HES1 expression compared to that in Caco-2 cells cultured in regular media. Significant amounts of interleukin-6 (IL-6) and IL-8 were detected in 18Co-CM compared to levels in regular media. The 18Co-CM-induced increase in CD133+CD44+ cells was attenuated by IL-6- and IL-8-neutralizing antibodies. Furthermore, these neutralizing antibodies and inhibitors of STAT3 and gamma-secretase reduced the expression of HES1 induced in Caco-2 cells cultured in 18Co-CM. Immunohistochemical analysis of human tissues revealed that IL-6, IL-8, and HES1 expression increased from normal to adenoma, and from adenoma to cancer tissues. In addition, IL-6 and HES1 expression was positively correlated in early colorectal cancer tissues. In conclusion, the increase of CSCs by myofibroblasts could be mediated by IL-6/IL-8-induced HES1 activation in the tumor microenvironment. Based on these data, the IL-6/IL-8-mediated Notch/HES1 and STAT3 pathway, through which CSCs interact with their microenvironment, might be a potential target for the prevention and treatment of colorectal tumors.

Bacteria\u2010derived ferrichrome inhibits tumor progression in sporadic colorectal neoplasms and colitis\u2010associated cancer

BackgroundColorectal cancers develop through several pathways, including the adenoma–carcinoma sequence and colitis-associated carcinogenesis. An altered intestinal microflora has been reported to be associated with the development and progression of colorectal cancer via these pathways. We identified Lactobacillus casei-derived ferrichrome as a mediator of the bacterial anti-tumor effect of colorectal cancer cells through the upregulation of DDIT3. In this study, we investigated the anti-tumor effects of ferrichrome on precancerous conditions and cancer cells associated with sporadic as well as colitis-associated colorectal cancer.MethodsSRB and MTT assays were performed to assess growth inhibition in vitro. Eighteen organoids were prepared from biopsy specimens obtained by colonoscopy. An AOM-DSS carcinogenesis model and xenograft model of colorectal cancer cells were generated for the assessment of the tumor suppressive effect of ferrichrome in vivo.ResultsFerrichrome inhibited the cell growth of colorectal cancer cells in vitro and in in vivo xenograft models. Ferrichrome exerted a strong tumor-suppressive effect that was superior to that of currently available anti-tumor agents, including 5-FU and cisplatin, both in vitro and in vivo. The tumor-suppressive effect of the combination of ferrichrome and 5-FU was superior to that of single treatment with either drug. The tumor suppressive effects of ferrichrome were confirmed through the upregulation of DDIT3 in patient-derived organoids of adenoma and carcinoma. Ferrichrome inhibited the tumor progression in the AOM-DSS model while exhibiting no anti-inflammatory effect in the DSS-colitis model, suggesting that ferrichrome inhibited cancer cells, but not a precancerous condition, via the colitis-associated pathway.ConclusionsFerrichrome exerts a tumor suppressive effect on precancerous conditions and cancer cells associated with sporadic as well as colitis-associated colorectal cancer. The anti-tumor effect of ferrichrome was mediated by the upregulation of DDIT3, and was superior to that of 5-FU or cisplatin. These results suggest that Lactobacillus brevis-derived ferrichrome may be a candidate anti-tumor drug for the treatment of colorectal neoplasms.

First experience of one and two-step endoscopic submucosal dissection of colorectal neoplasms

Aim. To analyze the results of one and two-step endoscopic submucosal dissection in the treatment of colorectal neoplasms.&#x0D; Methods. Between 2018 and 2019, 17 patients (6 men and 11 women) aged 33 to 79 years underwent 21 endoscopic submucosal dissections of colorectal neoplasms ranging in size from 1.0 to 6.0 cm. Submucosal fibrosis was identified in 2 (11.8%) patients, epithelial neoplasms in 15 (88.2%) patients including laterally spreading tumors in 9 (60%), and large sessile colorectal polyps in 6 (40%) patients. Histological examination revealed a carcinoid tumor (11.8%), adenoma with low-grade (64.7%) and high-grade (23.5%) intraepithelial neoplasia. 13 patients were subjected to the one-step operation, and 4 patients required the two-step operation with a 1-day interval. Follow-up examinations after the operation were performed, on average, between 2 and 6 months.&#x0D; Results. En bloc endoscopic submucosal dissection was performed in 11 (64.7%) patients, 4 of them in combination with mucosal resection. Endoscopic piecemeal resection of the neoplasia was performed in 6 (35.3%) patients. The average operative time was 15573 minutes (range 40320 min). Intraoperative complications, which were eliminated endoscopically, occurred during 8 (38.1%) of 21 operations: intensive bleeding in 6 (75%) patients, diastasis of muscle fibers in 1 (12.5%) patient, perforation of the intestinal wall in 1 (12.5%) patient. At the follow-up at 6 months, all patients formed the scar at the surgical area, while 3 patients required endoscopic removal of residual adenoma 2 months after the operation.&#x0D; Conclusion. Endoscopic submucosal dissection is an effective method for removing colorectal neoplasms, while two-step dissection is a promising approach to the development of the technique.Keywords: one and two-step dissection, endoscopic submucosal dissection (ESD), colorectal neoplasms.

Возможности повышения эффективности диагностики и лечения новообразований ободочной и прямой кишки (на примере работы Хабаровского краевого колопроктологического центра)

The paper analyses activities of the Khabarovsk Regional Coloproctological Center (KhRCC) that includes coloproctological, surgical and endoscopic units of the Khabarovsk City Hospital № 10 and provides diagnostics and treatment of colorectal neoplasms. It was found out that for the last 3 years KhRCC has significantly increased the number of colonoscopies (from 436 to 1 388), the number of detected early rectal cancer cases (from 8 to 39), the amount of benign colorectal neoplasms (from 605 to 2 308) and total number of patients treated for benign (from 147 to 427) and malignant (from 50 to 81) colorectal neoplasms. The conclusion can be made that the organization of regional centers for coloproctology and the implementation of activities, including changing the regulatory framework and making a clear road map for patients with benign and malignant colorectal neoplasms, positively influences the quality and availability of medical care for this pathology.

Surgical Outcomes of Laparoscopic Right Colectomy with Complete Mesocolic Excision.

Background and Objectives:Literature demonstrates that colorectal cancer is nowadays one of the most common malignancies. Laparoscopy and robotic surgery are progressively gaining popularity in the treatment of colorectal tumors. Complete mesocolic excision and central vascular ligation have been widely adopted with encouraging results in terms of an improvement of overall survival, but some studies in the literature seem to demonstrate a higher morbidity rate.Methods:We conducted a retrospective study from 01/01/2010 to 30/04/2019 on a series of 250 patients, 155 males (62%) and 95 females (38%) who underwent right colectomy with minimally invasive approach, complete mesocolic excision, central vascular ligation, and intracorporeal anastomosis.Results:No perioperative mortality occurred. Postoperative morbidity rate was 6%, including 10 cases of anastomotic leak (5%). Conversion rate was 2.5%. Mean hospital stay was 6 days (range, 4–25 days). Mean operative time was 70 minutes (range, 50–130 minutes). No cases of duodenal or pancreatic damages, no chronic pain or diarrhea, and no severe alteration of bowel function were recorded. We observed only 3 cases of transient delayed gastric emptying.Conclusions:Laparoscopic right colectomy with complete mesocolic excision, central vascular ligation and intracorporeal anastomosis leads to encouraging oncological mid- and long-term outcomes with low complications rates.

CL-43, a New Inhibitor of HSF1 Activity, Inhibits Epithelial-Mesenchymal Transition of DLD1 Colon Cancer Cells

Colorectal cancer is highly metastatic. In a quarter of patients with tumors of this type, liver metastases are detected already at the time of diagnosis. Therefore, the search for drugs that can reduce the metastatic activity of cells is an important task. A tumor experiences constant stress, resulting in an increased activity of the transcription factor HSF1, which is able to trigger the synthesis of heat shock proteins. This increases the resistance of cancer cells to both stress and antitumor therapy. It has been shown recently that HSF1 plays a critical role in the process of the epithelial–mesenchymal transition (EMT) underling the formation of metastases. Here, we show that a new inhibitor of HSF1 activity, CL-43, is capable of suppressing EMT that is induced by TGFβ1. CL-43 significantly reduced the migration and proliferative potency of DLD1 cells treated with TGFβ1. Analysis of vimentin level showed that cell treatment with CL-43 cells reduced this EMT marker and returned the expression and localization of E-cadherin in the cells to the original pattern. These findings suggest that CL-43 has therapeutic potential for treatment of colorectal tumors.

Developments in the study of gastrointestinal microbiome disorders affected by FGF19 in the occurrence and development of colorectal neoplasms.

Colorectal neoplasms are a type of malignant digestive system tumor that has become the third-highest morbidity tumor in China and the fourth leading cause of cancer-related death worldwide. The role of the gastrointestinal (GI) microbiome in bile acid metabolism, inflammation, and insulin resistance and its strong correlation with the occurrence and development of colorectal neoplasms have gradually led to it becoming a target area of tumor research. Fibroblast growth factor (FGF) 19 is a hormone that is secreted in mainly the ileum and can regulate bile acid biosynthesis, improve inflammation, and regulate insulin resistance. The relationship of the GI microbiome, FGF19 and its carcinogenic activities in colorectal neoplasms enticed us to search for potential targets and research ideas for the clinical diagnosis and treatment of colorectal neoplasms.

Colorectal robotic surgery: INCA's experience

IntroductionMinimally invasive surgery has revolutionized surgical management in the treatment of colorectal neoplasms, reducing morbidity and mortality, hospitalization, inactivity time and minimizing cost, as well as providing adequate oncological results when compared to the conventional approach. Robotic surgery, with Da Vinci Platform, emerges as a step ahead for its potentials. The objective of this article is to report the single institutional experience with the use of Da Vinci Platform in robotic colorectal surgeries performed at a reference center in oncological surgery in Brazil. Materials and methodsA retrospective cohort study was conducted based on the prospective database of patients from the institution submitted to robotic surgery for treatment of colorectal cancer from July 2012 to September 2017. Clinical and surgical variables were analyzed as predictors of morbidity and mortality. ResultsA total of 117 patients underwent robotic surgery. The complications related to surgery occurred in 33 patients (28%), the most frequent being anastomotic fistula and surgical wound infection, which corresponded to 11% and 3%, respectively. Conversion rate was 1.7%. Median length of stay was 5 days. The only variable associated with increase of complications and death risk was BMI >30, with p-value of 0.038 and 0.027, respectively. ConclusionRobotic surgery is safe and feasible for approaching colorectal cancer surgeries, presenting satisfactory results regarding length of hospital stay and rate of operative complications, as well as presenting a low rate of conversion. Obesity has been shown to be a risk factor for surgical complication in robotic colorectal surgery.

Short-term outcomes of endoscopic submucosal dissection versus laparoscopic surgery for colorectal neoplasms: An observational study

Objectives: With endoscopic submucosal dissection and laparoscopic surgery, treatment for colorectal neoplasms has become minimally invasive. However, few studies have compared endoscopic submucosal dissection with laparoscopic surgery for colorectal neoplasms, excluding deeply invasive cancer on preoperative diagnosis. Methods: We retrospectively reviewed the files of patients who had undergone endoscopic submucosal dissection or laparoscopic surgery for colorectal neoplasms between November 2005 and December 2015. We limited patients who were not suspected preoperatively to have aggressive submucosal invasion >1,000 μm. Results: Ninety-five patients underwent endoscopic submucosal dissection and 37 underwent laparoscopic surgery. Cases of endoscopic submucosal dissection tended to involve rectal neoplasms more often than colonic neoplasms, shorter operative times, and shorter lengths of hospital stay compared with laparoscopic surgery. The perforation rate during colonic endoscopic submucosal dissection in the early period (November 2005 to December 2010) and late period (January 2011 to December 2015) was 14.8% and 2.9%, respectively. In all cases of perforation during colonic endoscopic submucosal dissection, the ability to maneuver the endoscope was compromised. Though tumors were larger in patients who underwent rectal endoscopic submucosal dissection compared with colonic endoscopic submucosal dissection, the perforation and postoperative bleeding rates with rectal endoscopic submucosal dissection were both 3.2%. The most common indication for laparoscopic surgery was difficulty performing endoscopic submucosal dissection. Serious complications were rare. Conclusions: For colonic neoplasms, laparoscopic surgery should be considered when endoscopic submucosal dissection is technically difficult in the early period. For rectal neoplasms, endoscopic submucosal dissection is desirable even for those of large size.